Asymchem’s API plant gets passing grade from Australian regulators

China flag
Asymchem Laboratories’ API plant in Dunhua successfully passed an inspection by Australian drug regulators.

Chinese drugmaker Asymchem Laboratories’ API plant in Dunhua successfully passed an inspection by Australian drug regulators for a second consecutive time, the company said.

Inspectors from the Australian Therapeutic Goods Administration (TGA) conducted a 4-day inspection of the plant in June as part of a reinspection to extend a GMP certificate for an Asymchem client’s NDA filing. The previous TGA inspection was done in May.

The June inspection at Dunhua resulted in an A1 compliance rating. The plant was visited by FDA inspectors in March and no Form 483 was issued, the company said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The site produces small-molecule advanced intermediate and API for the pharmaceuticals market as well as handling hazardous chemicals on an industrial scale.

The passing grade reaffirms “our continuous investment in infrastructure and compliance towards meeting the highest quality standards in the API manufacturing arena,” Hao Hong, Ph.D., Asymchem’s CEO and chairman, said in a statement.

The company operates six facilities in China that specialize in areas that include biotransformation, flow chemistry, highly potent compounds, asymmetric synthesis, high-pressure and low-temperature chemistry.

Suggested Articles

Mylan is recalling a chemo drug and Hospira a commonly used solution because potentially dangerous particulate has been discovered in vials.

Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.

Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.